DBD vs DAVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

DBD

36.2
AI Score
VS
DAVE Wins

DAVE

39.8
AI Score

Investment Advisor Scores

DBD

36score
Recommendation
AVOID NEW MONEY

DAVE

40score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric DBD DAVE Winner
Forward P/E 12.1655 16.8634 DBD
PEG Ratio 0 0 Tie
Revenue Growth 1.7% 29.6% DAVE
Earnings Growth 34.2% -21.0% DBD
Tradestie Score 36.2/100 39.8/100 DAVE
Profit Margin 2.9% 34.6% DAVE
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY EXTENDED DAVE

Relative Price Performance (Last 90 Days)

DBD 1M: +5.9% · 3M: -21.6% DAVE 1M: +6.6% · 3M: -7.8%

Current Technical Phase

DBD

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 60

RSI (14): 60.3 · Price: $68.16

DAVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 57.8 · Price: $376.76

Fundamentals Snapshot

Metric DBD DAVE
Market Cap — —
Forward P/E 9.7 16.9
Trailing P/E 22.4 23.4
Revenue (TTM) — —
Revenue Growth 0.0% 0.3%
Gross Margin 0.3% 0.7%
Operating Margin 0.1% 0.3%
EPS 3.03 15.51
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DAVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.